JZP 898
Alternative Names: JZP-898; WTX-613Latest Information Update: 01 Sep 2026
At a glance
- Originator Werewolf Therapeutics
- Developer Jazz Pharmaceuticals plc; Werewolf Therapeutics
- Class Antineoplastics; Immunotherapies; Interferons
- Mechanism of Action Interferon alpha-2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Lymphoma
- Research Haematological malignancies
Most Recent Events
- 17 Apr 2026 Adverse events data from a preclinical trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 31 Dec 2023 Werewolf Therapeutics has pending patent application for JZP 898 in Australia, Canada, Japan, USA, before December 2023
- 31 Dec 2023 Werewolf Therapeutics has pending US provisional patent application for certain methods of use with respect to WTX 613 in USA prior to December 2023